Eledon Pharmaceuticals, Inc.
ELDN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.06 | -0.06 | 0.11 | 0.01 |
| FCF Yield | -7.24% | -8.47% | -6.14% | -7.71% |
| EV / EBITDA | -11.28 | -8.25 | -39.08 | -5.14 |
| Quality | ||||
| ROIC | -16.45% | -18.80% | -11.78% | -14.86% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.83 | 1.58 | 2.47 | 0.43 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 18.27% | -10.29% | 15.42% | -61.33% |
| Safety | ||||
| Net Debt / EBITDA | 0.17 | 0.20 | 1.17 | 0.44 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -5,965.57 |